Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review
Cardiovascular disease in patients with systemic lupus erythematosus (SLE) remains one of the most common causes of death and is caused by several factors, including both traditional and disease-specific risk factors. We aimed to systematically appraise the evidence of cardiovascular disease risk fa...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2023-11, Vol.42 (11), p.2931-2941 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2941 |
|---|---|
| container_issue | 11 |
| container_start_page | 2931 |
| container_title | Clinical rheumatology |
| container_volume | 42 |
| creator | Katayama, Yu Yanai, Ryo Itaya, Takahiro Nagamine, Yusuke Tanigawa, Kyosuke Miyawaki, Yoshia |
| description | Cardiovascular disease in patients with systemic lupus erythematosus (SLE) remains one of the most common causes of death and is caused by several factors, including both traditional and disease-specific risk factors. We aimed to systematically appraise the evidence of cardiovascular disease risk factors focusing on the SLE population. The protocol for this umbrella review is registered in PROSPERO (registration no. CRD42020206858). A systematic literature search was conducted in PubMed, Embase, and the Cochrane Library from database inception to June 22, 2022, for systematic reviews and meta-analyzes that examined cardiovascular disease risk factors in patients with SLE. Two reviewers independently extracted data and assessed the quality of the included studies using the “Assessing the Methodological Quality of Systematic Reviews 2 (AMSTER 2)” tool. Of the 102 identified articles, nine systematic reviews were included in this umbrella review. All included systematic reviews were assessed as critically low quality according to the AMSTER 2 tool. The traditional risk factors identified in this study were older age, male sex, hypertension, dyslipidemia, smoking, and a family history of cardiovascular disease. SLE-specific risk factors were long-term disease duration, lupus nephritis, neurological disorders, high disease activity, organ damage, use of glucocorticoids, azathioprine, and antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant. This umbrella review identified some cardiovascular disease risk factors in patients with SLE; however, the study quality of all included systematic reviews was critically low.
Key Points
• We examined the evidence of cardiovascular disease risk factors focusing on patients with systemic lupus erythematosus.
• We found that long-term disease duration, lupus nephritis, neurological disorders, high disease activity, organ damage, use of glucocorticoids, azathioprine, and antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant, were cardiovascular disease risk factors among patients with systemic lupus erythematosus.
• The review indicates the need for well-validated and high-quality future reviews that assess major adverse cardiovascular events as an outcome in patients with systemic lupus erythematosus. |
| doi_str_mv | 10.1007/s10067-023-06608-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2810916656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2878917219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-2fdf366d2592e4fe88df9535e3ca3844bf826f70e3a9e20e705ff829338c32013</originalsourceid><addsrcrecordid>eNp9kU1rVDEUhoModlr9Ay5KwI2bW_Nxbz7cSdG2UBBE1yFz74nNeD-mOUnL_HszTm2hCzcJ5Dx5zuG8hLzj7Iwzpj9iPZVumJANU4qZRr0gK97KtrG2tS_JimnNGsmtOSLHiBvGmDCWvyZHUvNWGNWuyOZ7xN80-D4vCWlYEu19GuJy57Evo090iAgeAWmc6dbnCHNGeh_zDcUdZphiT8eyLUgh7fINTD4vWPAT9TMt0zrBOHqa4C7C_RvyKvgR4e3DfUJ-fv3y4_yyuf52cXX--brppVC5EWEIUqlBdFZAG8CYIdhOdiB7L03broMRKmgG0lsQDDTrQn2yUpoqYFyekA8H7zYttwUwuylivx9khqWgE4Yzy5XqVEXfP0M3S0lzna5Suu5KC24rJQ5UnxbEBMFtU5x82jnO3D4Jd0jC1STc3yTcXn36oC7rCYbHL_9WXwF5ALCW5l-Qnnr_R_sH_QiU6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2878917219</pqid></control><display><type>article</type><title>Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review</title><source>MEDLINE</source><source>SpringerNature Complete Journals</source><creator>Katayama, Yu ; Yanai, Ryo ; Itaya, Takahiro ; Nagamine, Yusuke ; Tanigawa, Kyosuke ; Miyawaki, Yoshia</creator><creatorcontrib>Katayama, Yu ; Yanai, Ryo ; Itaya, Takahiro ; Nagamine, Yusuke ; Tanigawa, Kyosuke ; Miyawaki, Yoshia</creatorcontrib><description>Cardiovascular disease in patients with systemic lupus erythematosus (SLE) remains one of the most common causes of death and is caused by several factors, including both traditional and disease-specific risk factors. We aimed to systematically appraise the evidence of cardiovascular disease risk factors focusing on the SLE population. The protocol for this umbrella review is registered in PROSPERO (registration no. CRD42020206858). A systematic literature search was conducted in PubMed, Embase, and the Cochrane Library from database inception to June 22, 2022, for systematic reviews and meta-analyzes that examined cardiovascular disease risk factors in patients with SLE. Two reviewers independently extracted data and assessed the quality of the included studies using the “Assessing the Methodological Quality of Systematic Reviews 2 (AMSTER 2)” tool. Of the 102 identified articles, nine systematic reviews were included in this umbrella review. All included systematic reviews were assessed as critically low quality according to the AMSTER 2 tool. The traditional risk factors identified in this study were older age, male sex, hypertension, dyslipidemia, smoking, and a family history of cardiovascular disease. SLE-specific risk factors were long-term disease duration, lupus nephritis, neurological disorders, high disease activity, organ damage, use of glucocorticoids, azathioprine, and antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant. This umbrella review identified some cardiovascular disease risk factors in patients with SLE; however, the study quality of all included systematic reviews was critically low.
Key Points
• We examined the evidence of cardiovascular disease risk factors focusing on patients with systemic lupus erythematosus.
• We found that long-term disease duration, lupus nephritis, neurological disorders, high disease activity, organ damage, use of glucocorticoids, azathioprine, and antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant, were cardiovascular disease risk factors among patients with systemic lupus erythematosus.
• The review indicates the need for well-validated and high-quality future reviews that assess major adverse cardiovascular events as an outcome in patients with systemic lupus erythematosus.</description><identifier>ISSN: 0770-3198</identifier><identifier>ISSN: 1434-9949</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-023-06608-6</identifier><identifier>PMID: 37142864</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antibodies ; Antibodies, Anticardiolipin ; Antibodies, Antiphospholipid ; Anticoagulants ; Antiphospholipid antibodies ; Antiphospholipid Syndrome ; Azathioprine ; Cardiolipin ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - epidemiology ; Dyslipidemia ; Glucocorticoids ; Humans ; Lupus ; Lupus Coagulation Inhibitor ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - epidemiology ; Lupus Nephritis ; Male ; Medicine ; Medicine & Public Health ; Meta-analysis ; Nervous System Diseases ; Neurological diseases ; Neurological disorders ; Review Article ; Rheumatology ; Risk Factors ; Systematic Reviews as Topic ; Systemic lupus erythematosus</subject><ispartof>Clinical rheumatology, 2023-11, Vol.42 (11), p.2931-2941</ispartof><rights>The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-2fdf366d2592e4fe88df9535e3ca3844bf826f70e3a9e20e705ff829338c32013</cites><orcidid>0000-0002-0560-8686 ; 0000-0002-0443-5007 ; 0000-0002-6981-3443 ; 0000-0003-3611-2525 ; 0000-0003-3118-7675 ; 0000-0002-6192-9855</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-023-06608-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-023-06608-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37142864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katayama, Yu</creatorcontrib><creatorcontrib>Yanai, Ryo</creatorcontrib><creatorcontrib>Itaya, Takahiro</creatorcontrib><creatorcontrib>Nagamine, Yusuke</creatorcontrib><creatorcontrib>Tanigawa, Kyosuke</creatorcontrib><creatorcontrib>Miyawaki, Yoshia</creatorcontrib><title>Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>Cardiovascular disease in patients with systemic lupus erythematosus (SLE) remains one of the most common causes of death and is caused by several factors, including both traditional and disease-specific risk factors. We aimed to systematically appraise the evidence of cardiovascular disease risk factors focusing on the SLE population. The protocol for this umbrella review is registered in PROSPERO (registration no. CRD42020206858). A systematic literature search was conducted in PubMed, Embase, and the Cochrane Library from database inception to June 22, 2022, for systematic reviews and meta-analyzes that examined cardiovascular disease risk factors in patients with SLE. Two reviewers independently extracted data and assessed the quality of the included studies using the “Assessing the Methodological Quality of Systematic Reviews 2 (AMSTER 2)” tool. Of the 102 identified articles, nine systematic reviews were included in this umbrella review. All included systematic reviews were assessed as critically low quality according to the AMSTER 2 tool. The traditional risk factors identified in this study were older age, male sex, hypertension, dyslipidemia, smoking, and a family history of cardiovascular disease. SLE-specific risk factors were long-term disease duration, lupus nephritis, neurological disorders, high disease activity, organ damage, use of glucocorticoids, azathioprine, and antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant. This umbrella review identified some cardiovascular disease risk factors in patients with SLE; however, the study quality of all included systematic reviews was critically low.
Key Points
• We examined the evidence of cardiovascular disease risk factors focusing on patients with systemic lupus erythematosus.
• We found that long-term disease duration, lupus nephritis, neurological disorders, high disease activity, organ damage, use of glucocorticoids, azathioprine, and antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant, were cardiovascular disease risk factors among patients with systemic lupus erythematosus.
• The review indicates the need for well-validated and high-quality future reviews that assess major adverse cardiovascular events as an outcome in patients with systemic lupus erythematosus.</description><subject>Antibodies</subject><subject>Antibodies, Anticardiolipin</subject><subject>Antibodies, Antiphospholipid</subject><subject>Anticoagulants</subject><subject>Antiphospholipid antibodies</subject><subject>Antiphospholipid Syndrome</subject><subject>Azathioprine</subject><subject>Cardiolipin</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Dyslipidemia</subject><subject>Glucocorticoids</subject><subject>Humans</subject><subject>Lupus</subject><subject>Lupus Coagulation Inhibitor</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - epidemiology</subject><subject>Lupus Nephritis</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Nervous System Diseases</subject><subject>Neurological diseases</subject><subject>Neurological disorders</subject><subject>Review Article</subject><subject>Rheumatology</subject><subject>Risk Factors</subject><subject>Systematic Reviews as Topic</subject><subject>Systemic lupus erythematosus</subject><issn>0770-3198</issn><issn>1434-9949</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU1rVDEUhoModlr9Ay5KwI2bW_Nxbz7cSdG2UBBE1yFz74nNeD-mOUnL_HszTm2hCzcJ5Dx5zuG8hLzj7Iwzpj9iPZVumJANU4qZRr0gK97KtrG2tS_JimnNGsmtOSLHiBvGmDCWvyZHUvNWGNWuyOZ7xN80-D4vCWlYEu19GuJy57Evo090iAgeAWmc6dbnCHNGeh_zDcUdZphiT8eyLUgh7fINTD4vWPAT9TMt0zrBOHqa4C7C_RvyKvgR4e3DfUJ-fv3y4_yyuf52cXX--brppVC5EWEIUqlBdFZAG8CYIdhOdiB7L03broMRKmgG0lsQDDTrQn2yUpoqYFyekA8H7zYttwUwuylivx9khqWgE4Yzy5XqVEXfP0M3S0lzna5Suu5KC24rJQ5UnxbEBMFtU5x82jnO3D4Jd0jC1STc3yTcXn36oC7rCYbHL_9WXwF5ALCW5l-Qnnr_R_sH_QiU6Q</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Katayama, Yu</creator><creator>Yanai, Ryo</creator><creator>Itaya, Takahiro</creator><creator>Nagamine, Yusuke</creator><creator>Tanigawa, Kyosuke</creator><creator>Miyawaki, Yoshia</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0560-8686</orcidid><orcidid>https://orcid.org/0000-0002-0443-5007</orcidid><orcidid>https://orcid.org/0000-0002-6981-3443</orcidid><orcidid>https://orcid.org/0000-0003-3611-2525</orcidid><orcidid>https://orcid.org/0000-0003-3118-7675</orcidid><orcidid>https://orcid.org/0000-0002-6192-9855</orcidid></search><sort><creationdate>20231101</creationdate><title>Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review</title><author>Katayama, Yu ; Yanai, Ryo ; Itaya, Takahiro ; Nagamine, Yusuke ; Tanigawa, Kyosuke ; Miyawaki, Yoshia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-2fdf366d2592e4fe88df9535e3ca3844bf826f70e3a9e20e705ff829338c32013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Antibodies, Anticardiolipin</topic><topic>Antibodies, Antiphospholipid</topic><topic>Anticoagulants</topic><topic>Antiphospholipid antibodies</topic><topic>Antiphospholipid Syndrome</topic><topic>Azathioprine</topic><topic>Cardiolipin</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Dyslipidemia</topic><topic>Glucocorticoids</topic><topic>Humans</topic><topic>Lupus</topic><topic>Lupus Coagulation Inhibitor</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - epidemiology</topic><topic>Lupus Nephritis</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Nervous System Diseases</topic><topic>Neurological diseases</topic><topic>Neurological disorders</topic><topic>Review Article</topic><topic>Rheumatology</topic><topic>Risk Factors</topic><topic>Systematic Reviews as Topic</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katayama, Yu</creatorcontrib><creatorcontrib>Yanai, Ryo</creatorcontrib><creatorcontrib>Itaya, Takahiro</creatorcontrib><creatorcontrib>Nagamine, Yusuke</creatorcontrib><creatorcontrib>Tanigawa, Kyosuke</creatorcontrib><creatorcontrib>Miyawaki, Yoshia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katayama, Yu</au><au>Yanai, Ryo</au><au>Itaya, Takahiro</au><au>Nagamine, Yusuke</au><au>Tanigawa, Kyosuke</au><au>Miyawaki, Yoshia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>42</volume><issue>11</issue><spage>2931</spage><epage>2941</epage><pages>2931-2941</pages><issn>0770-3198</issn><issn>1434-9949</issn><eissn>1434-9949</eissn><abstract>Cardiovascular disease in patients with systemic lupus erythematosus (SLE) remains one of the most common causes of death and is caused by several factors, including both traditional and disease-specific risk factors. We aimed to systematically appraise the evidence of cardiovascular disease risk factors focusing on the SLE population. The protocol for this umbrella review is registered in PROSPERO (registration no. CRD42020206858). A systematic literature search was conducted in PubMed, Embase, and the Cochrane Library from database inception to June 22, 2022, for systematic reviews and meta-analyzes that examined cardiovascular disease risk factors in patients with SLE. Two reviewers independently extracted data and assessed the quality of the included studies using the “Assessing the Methodological Quality of Systematic Reviews 2 (AMSTER 2)” tool. Of the 102 identified articles, nine systematic reviews were included in this umbrella review. All included systematic reviews were assessed as critically low quality according to the AMSTER 2 tool. The traditional risk factors identified in this study were older age, male sex, hypertension, dyslipidemia, smoking, and a family history of cardiovascular disease. SLE-specific risk factors were long-term disease duration, lupus nephritis, neurological disorders, high disease activity, organ damage, use of glucocorticoids, azathioprine, and antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant. This umbrella review identified some cardiovascular disease risk factors in patients with SLE; however, the study quality of all included systematic reviews was critically low.
Key Points
• We examined the evidence of cardiovascular disease risk factors focusing on patients with systemic lupus erythematosus.
• We found that long-term disease duration, lupus nephritis, neurological disorders, high disease activity, organ damage, use of glucocorticoids, azathioprine, and antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant, were cardiovascular disease risk factors among patients with systemic lupus erythematosus.
• The review indicates the need for well-validated and high-quality future reviews that assess major adverse cardiovascular events as an outcome in patients with systemic lupus erythematosus.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>37142864</pmid><doi>10.1007/s10067-023-06608-6</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0560-8686</orcidid><orcidid>https://orcid.org/0000-0002-0443-5007</orcidid><orcidid>https://orcid.org/0000-0002-6981-3443</orcidid><orcidid>https://orcid.org/0000-0003-3611-2525</orcidid><orcidid>https://orcid.org/0000-0003-3118-7675</orcidid><orcidid>https://orcid.org/0000-0002-6192-9855</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2023-11, Vol.42 (11), p.2931-2941 |
| issn | 0770-3198 1434-9949 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2810916656 |
| source | MEDLINE; SpringerNature Complete Journals |
| subjects | Antibodies Antibodies, Anticardiolipin Antibodies, Antiphospholipid Anticoagulants Antiphospholipid antibodies Antiphospholipid Syndrome Azathioprine Cardiolipin Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - epidemiology Dyslipidemia Glucocorticoids Humans Lupus Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - epidemiology Lupus Nephritis Male Medicine Medicine & Public Health Meta-analysis Nervous System Diseases Neurological diseases Neurological disorders Review Article Rheumatology Risk Factors Systematic Reviews as Topic Systemic lupus erythematosus |
| title | Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A33%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20for%20cardiovascular%20diseases%20in%20patients%20with%20systemic%20lupus%20erythematosus:%20an%20umbrella%20review&rft.jtitle=Clinical%20rheumatology&rft.au=Katayama,%20Yu&rft.date=2023-11-01&rft.volume=42&rft.issue=11&rft.spage=2931&rft.epage=2941&rft.pages=2931-2941&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-023-06608-6&rft_dat=%3Cproquest_cross%3E2878917219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2878917219&rft_id=info:pmid/37142864&rfr_iscdi=true |